Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

M. Rieken; L. A. Kluth; E. Xylinas; C. Seitz; H. Fajkovic; P. I. Karakiewicz; Yair Lotan; A. Briganti; W. Loidl; T. Faison; J. J. Crivelli; D. S. Scherr; A. Bachmann; A. K. Tewari; A. Kautzky-Willer; K. Pummer; S. F. Shariat

doi:10.1038/pcan.2013.31

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

M. Rieken, L. A. Kluth, E. Xylinas, C. Seitz, H. Fajkovic, P. I. Karakiewicz, Yair Lotan, A. Briganti, W. Loidl, T. Faison, J. J. Crivelli, D. S. Scherr, A. Bachmann, A. K. Tewari, A. Kautzky-Willer, K. Pummer, S. F. Shariat

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background:The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR.Results:Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values ≤0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.Conclusions:In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.

Original language	English (US)
Pages (from-to)	367-371
Number of pages	5
Journal	Prostate Cancer and Prostatic Diseases
Volume	16
Issue number	4
DOIs	https://doi.org/10.1038/pcan.2013.31
State	Published - Dec 2013

Keywords

Biochemical recurrence
Radical prostatectomy
Statins

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

Access to Document

10.1038/pcan.2013.31

Cite this

Rieken, M., Kluth, L. A., Xylinas, E., Seitz, C., Fajkovic, H., Karakiewicz, P. I., Lotan, Y., Briganti, A., Loidl, W., Faison, T., Crivelli, J. J., Scherr, D. S., Bachmann, A., Tewari, A. K., Kautzky-Willer, A., Pummer, K., & Shariat, S. F. (2013). Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases, 16(4), 367-371. https://doi.org/10.1038/pcan.2013.31

Rieken, M, Kluth, LA, Xylinas, E, Seitz, C, Fajkovic, H, Karakiewicz, PI, Lotan, Y, Briganti, A, Loidl, W, Faison, T, Crivelli, JJ, Scherr, DS, Bachmann, A, Tewari, AK, Kautzky-Willer, A, Pummer, K & Shariat, SF 2013, 'Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy', Prostate Cancer and Prostatic Diseases, vol. 16, no. 4, pp. 367-371. https://doi.org/10.1038/pcan.2013.31

@article{93e17da10c004c92b5573e57d3f35252,

title = "Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy",

abstract = "Background:The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR.Results:Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values ≤0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.Conclusions:In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.",

keywords = "Biochemical recurrence, Radical prostatectomy, Statins",

author = "M. Rieken and Kluth, {L. A.} and E. Xylinas and C. Seitz and H. Fajkovic and Karakiewicz, {P. I.} and Yair Lotan and A. Briganti and W. Loidl and T. Faison and Crivelli, {J. J.} and Scherr, {D. S.} and A. Bachmann and Tewari, {A. K.} and A. Kautzky-Willer and K. Pummer and Shariat, {S. F.}",

note = "Funding Information: M. Rieken received Grant Support from Swiss National Science Foundation. A. Bachmann is the company consult for American Medical Systems, Caris Life Sciences, Olympus, Orion Pharma, Schering. S.F. Shariat is the member of Advisory Board for Ferring Pharmaceuticals. The remaining authors declare no conflict of interest.",

year = "2013",

month = dec,

doi = "10.1038/pcan.2013.31",

language = "English (US)",

volume = "16",

pages = "367--371",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

AU - Rieken, M.

AU - Kluth, L. A.

AU - Xylinas, E.

AU - Seitz, C.

AU - Fajkovic, H.

AU - Karakiewicz, P. I.

AU - Lotan, Yair

AU - Briganti, A.

AU - Loidl, W.

AU - Faison, T.

AU - Crivelli, J. J.

AU - Scherr, D. S.

AU - Bachmann, A.

AU - Tewari, A. K.

AU - Kautzky-Willer, A.

AU - Pummer, K.

AU - Shariat, S. F.

N1 - Funding Information: M. Rieken received Grant Support from Swiss National Science Foundation. A. Bachmann is the company consult for American Medical Systems, Caris Life Sciences, Olympus, Orion Pharma, Schering. S.F. Shariat is the member of Advisory Board for Ferring Pharmaceuticals. The remaining authors declare no conflict of interest.

PY - 2013/12

Y1 - 2013/12

N2 - Background:The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR.Results:Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values ≤0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.Conclusions:In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.

AB - Background:The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR.Results:Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values ≤0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.Conclusions:In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.

KW - Biochemical recurrence

KW - Radical prostatectomy

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84887613699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887613699&partnerID=8YFLogxK

U2 - 10.1038/pcan.2013.31

DO - 10.1038/pcan.2013.31

M3 - Article

C2 - 23999669

AN - SCOPUS:84887613699

SN - 1365-7852

VL - 16

SP - 367

EP - 371

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 4

ER -

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this